Loading...
Alterity Therapeutics Limited
PRNAF•PNK
Healthcare
Biotechnology
$0.003
$0.00(0.00%)
Alterity Therapeutics Limited (PRNAF) Financial Performance & Income Statement Overview
Review Alterity Therapeutics Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
2.63%
↑ 2.63%
Operating Income Growth
-33.93%
↓ 33.93%
Net Income Growth
-38.51%
↓ 38.51%
Operating Cash Flow Growth
37.08%
↑ 37.08%
Operating Margin
-487.69%
↓ 487.69%
Gross Margin
94.67%
↑ 94.67%
Net Profit Margin
-475.79%
↓ 475.79%
ROE
-177.20%
↓ 177.20%
ROIC
-250.37%
↓ 250.37%
Alterity Therapeutics Limited (PRNAF) Income Statement & Financial Overview
Review Alterity Therapeutics Limited's (PRNAF) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $2.12M | $1.90M | $765247.00 | $765247.00 |
| Cost of Revenue | $73612.00 | $73917.00 | $52267.00 | $62517.00 |
| Gross Profit | $2.04M | $1.83M | $712980.00 | $702730.00 |
| Gross Profit Ratio | $0.97 | $0.96 | $0.93 | $0.92 |
| R&D Expenses | $12.28M | $6.36M | $5.43M | $2.72M |
| SG&A Expenses | $2.75M | $2.08M | $2.29M | $1.11M |
| Operating Expenses | $14.98M | $8.45M | $7.72M | $3.59M |
| Total Costs & Expenses | $15.10M | $8.52M | $7.77M | $3.65M |
| Interest Income | $150019.00 | $118400.00 | $5057.00 | $2528.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $73612.00 | $73917.00 | $52267.00 | $9091.00 |
| EBITDA | -$14.62M | -$8.33M | -$3.11M | -$3.11M |
| EBITDA Ratio | -$6.90 | -$4.44 | -$10.09 | -$4.07 |
| Operating Income | -$15.10M | -$8.52M | -$7.77M | -$3.12M |
| Operating Income Ratio | -$7.13 | -$4.48 | -$10.16 | -$4.08 |
| Other Income/Expenses (Net) | $412988.00 | $111345.00 | $234365.00 | $236314.00 |
| Income Before Tax | -$14.69M | -$8.41M | -$7.30M | -$2.89M |
| Income Before Tax Ratio | -$6.93 | -$4.42 | -$9.54 | -$3.77 |
| Income Tax Expense | -$2.07M | -$1.90M | -$1.53M | $280.00 |
| Net Income | -$12.62M | -$6.51M | -$5.77M | -$2.89M |
| Net Income Ratio | -$5.96 | -$3.42 | -$7.55 | -$3.77 |
| EPS | -$0.002 | -$0.003 | -$0.002 | -$0.001 |
| Diluted EPS | -$0.002 | -$0.003 | -$0.002 | -$0.001 |
| Weighted Avg Shares Outstanding | $6.31B | $2.50B | $2.44B | $2.41B |
| Weighted Avg Shares Outstanding (Diluted) | $6.31B | $2.50B | $2.44B | $2.44B |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan